Sign inJoin waitlistJoin the waitlist

Margo Hoover-Regan

Clinical Director · University of Wisconsin School of Medicine and Public Health

Credentials: · ·

History

Ann & Robert H Lurie Children's Hospital of Chicago
Pediatrics
University of Chicago Medical Center
University of Illinois College of Medicine
Northwestern University, Evanston, Illinois

Research

Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience
British Journal of Haematology · 2003 · 118 citations
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2025 · 76 citations
Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience
Review · American Journal of Hematology · 2003 · 33 citations

Adam Wolfe
2 papers · 1 as a fellow
AM
Anna Meadows
2 papers
Carl Kjeldsberg
2 papers
CD
Carol Diamond
2 papers
JF
Jonathan Finlay
2 papers
KD
Ken DeSantes
2 papers
ML
Mark Lones
2 papers
MK
Marshall Kadin
2 papers
Mitchell Cairo
2 papers
Sherrie Perkins
2 papers
SS
Stuart Siegel
2 papers
Alexandra Callan
1 paper

Clinical trials

Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy
Principal investigator · Terminated · Phase 1, Phase 2
University of Wisconsin, Madison
2015–2017
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029